Posner said in her filing that the price suppression or depreciation in light of the company sharing positive news is unnatural. Dumbing it down another way, my version - Pre-revenue Biotech stocks are rewarded with sp appreciation, as the company achieves foundational milestones. Unless circumstances or conditions change, which undermine the company's objectives going forward, there aren't enough, so-called, news worthy announcements to generate, especially while waiting for an approval, that could ever satisfy foot stomping, finger sucking babies crying because they wet their diapers.